- Home
- DRUG vs SGHT Comparison
DRUG vs SGHT Comparison
Compare DRUG & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- SGHT
- Stock Information
- Founded
- DRUG 2019
- SGHT 2011
- Country
- DRUG United States
- SGHT United States
- Employees
- DRUG N/A
- SGHT N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- SGHT Medical Specialities
- Sector
- DRUG Health Care
- SGHT Health Care
- Exchange
- DRUG Nasdaq
- SGHT Nasdaq
- Market Cap
- DRUG 199.7M
- SGHT 179.7M
- IPO Year
- DRUG N/A
- SGHT 2021
- Fundamental
- Price
- DRUG $33.63
- SGHT $3.27
- Analyst Decision
- DRUG Strong Buy
- SGHT Buy
- Analyst Count
- DRUG 7
- SGHT 8
- Target Price
- DRUG $83.25
- SGHT $3.87
- AVG Volume (30 Days)
- DRUG 37.4K
- SGHT 117.6K
- Earning Date
- DRUG 08-13-2025
- SGHT 08-07-2025
- Dividend Yield
- DRUG N/A
- SGHT N/A
- EPS Growth
- DRUG N/A
- SGHT N/A
- EPS
- DRUG N/A
- SGHT N/A
- Revenue
- DRUG N/A
- SGHT $78,109,000.00
- Revenue This Year
- DRUG N/A
- SGHT N/A
- Revenue Next Year
- DRUG N/A
- SGHT $11.22
- P/E Ratio
- DRUG N/A
- SGHT N/A
- Revenue Growth
- DRUG N/A
- SGHT N/A
- 52 Week Low
- DRUG $0.94
- SGHT $2.03
- 52 Week High
- DRUG $79.02
- SGHT $7.78
- Technical
- Relative Strength Index (RSI)
- DRUG 64.40
- SGHT 39.19
- Support Level
- DRUG $31.80
- SGHT $3.41
- Resistance Level
- DRUG $36.50
- SGHT $3.63
- Average True Range (ATR)
- DRUG 2.44
- SGHT 0.19
- MACD
- DRUG 0.79
- SGHT -0.02
- Stochastic Oscillator
- DRUG 70.86
- SGHT 23.19
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.